With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19
Vaccine Also Moving Towards Trials
Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.
